Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 醫學院
  3. 微生物學科所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38067
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor陳垣崇(Yuan-Tsong Chen)
dc.contributor.authorChi-Fan Yangen
dc.contributor.author楊奇凡zh_TW
dc.date.accessioned2021-06-13T15:59:47Z-
dc.date.available2011-08-13
dc.date.copyright2008-08-13
dc.date.issued2008
dc.date.submitted2008-04-29
dc.identifier.citationREFERENCES
Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192:681-694.
Adams L, Scott GK, Weinberg CS (1996) Biphasic modulation of cell growth by recombinant human galectin-1. Biochim Biophys Acta 1312:137-144.
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910-1914.
Ansaldi M, Lepelletier M, Mejean V (1996) Site-specific mutagenesis by using an accurate recombinant polymerase chain reaction method. Anal Biochem 234:110-111.
Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG (1999) The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113:752-759.
Baker BS, Griffiths CE, Lambert S, Powles AV, Leonard JN, Valdimarsson H, et al. (1987) The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 116:503-510.
Banno T, Adachi M, Mukkamala L, Blumenberg M (2003) Unique keratinocyte-specific effects of interferon-gamma that protect skin from viruses, identified using transcriptional profiling. Antivir Ther 8:541-554.
Banno T, Gazel A, Blumenberg M (2004) Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 279:32633-32642.
Barisic-Drusko V, Rucevic I (2004) Trigger factors in childhood psoriasis and vitiligo. Coll Antropol 28:277-285.
Begovich AB, Erlich HA (1995) HLA typing for bone marrow transplantation. New polymerase chain reaction-based methods. Jama 273:586-591.
Bhamidipati A, Lewis SA, Cowan NJ (2000) ADP ribosylation factor-like protein 2 (Arl2) regulates the interaction of tubulin-folding cofactor D with native tubulin. J Cell Biol 149:1087-1096.
Birnbaum RY, Zvulunov A, Hallel-Halevy D, Cagnano E, Finer G, Ofir R, et al. (2006) Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. NatGenet 38:749-751.
Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics of psoriasis. NatRevImmunol 5:699-711.
Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO (2004) Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199:731-736.
Brandrup F, Hauge M, Henningsen K, Eriksen B (1978) Psoriasis in an unselected series of twins. Arch Dermatol 114:874-878.
Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE (1982) Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 62:229-236.
Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, et al. (1998) Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 115:287-296.
Capon F, Novelli G, Semprini S, Clementi M, Nudo M, Vultaggio P, et al. (1999) Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 112:32-35.
Capon F, Semprini S, Chimenti S, Fabrizi G, Zambruno G, Murgia S, et al. (2001) Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 116:728-730.
Carrera AC, Rincon M, Sanchez-Madrid F, Lopez-Botet M, de Landazuri MO (1988) Triggering of co-mitogenic signals in T cell proliferation by anti-LFA-1 (CD18, CD11a), LFA-3, and CD7 monoclonal antibodies. JImmunol 141:1919-1924.
Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, et al. (2005) Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 102:2075-2080.
Chan AS, Mobley JL, Fields GB, Shimizu Y (1997) CD7-mediated regulation of integrin adhesiveness on human T cells involves tyrosine phosphorylation-dependent activation of phosphatidylinositol 3-kinase. JImmunol 159:934-942.
Choi YS, Sinha S (2006) Determination of the consensus DNA-binding sequence and a transcriptional activation domain for ESE-2. BiochemJ 398:497-507.
Chong BF, Wong HK (2007) Immunobiologics in the treatment of psoriasis. Clin Immunol 123:129-138.
da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, et al. (2002) Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 168:4462-4471.
Duffy DL, Spelman LS, Martin NG (1993) Psoriasis in Australian twins. J Am Acad Dermatol 29:428-434.
Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K (2004) S100 proteins in the epidermis. J Invest Dermatol 123:23-33.
Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ (1994) The genetics of psoriasis. Arch Dermatol 130:216-224.
Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. (1986) Cyclosporine improves psoriasis in a double-blind study. Jama 256:3110-3116.
Elola MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE (2005) Galectin-1 receptors in different cell types. JBiomedSci 12:13-29.
Enlund F, Samuelsson L, Enerback C, Inerot A, Wahlstrom J, Yhr M, et al. (1999a) Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. Hum Hered 49:2-8.
Enlund F, Samuelsson L, Enerback C, Inerot A, Wahlstrom J, Yhr M, et al. (1999b) Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur J Hum Genet 7:783-790.
Farber EM, Nall ML, Watson W (1974) Natural history of psoriasis in 61 twin pairs. Arch Dermatol 109:207-211.
Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM (2000) CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 14:63-78.
Finch PW, Murphy F, Cardinale I, Krueger JG (1997) Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol 151:1619-1628.
Fredriksson T, Pettersson U (1978) Severe psoriasis--oral therapy with a new retinoid. Dermatologica 157:238-244.
Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, et al. (2003) CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 63:8302-8311.
Giardina E, Capon F, De Rosa MC, Mango R, Zambruno G, Orecchia A, et al. (2004) Characterization of the loricrin (LOR) gene as a positional candidate for the PSORS4 psoriasis susceptibility locus. Ann Hum Genet 68:639-645.
Giardina E, Sinibaldi C, Chini L, Moschese V, Marulli G, Provini A, et al. (2006) Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21. Hum Hered 61:229-236.
Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, et al. (2004) Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 140:1490-1495.
Gillitzer R, Ritter U, Spandau U, Goebeler M, Brocker EB (1996) Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 107:778-782.
Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, et al. (2004) Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 6:R326-334.
Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ (2005) The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 153:945-953.
Gottlieb AB (2005) Psoriasis: emerging therapeutic strategies. NatRevDrug Discov 4:19-34.
Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. (2005) TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175:2721-2729.
Hebert SC, Mount DB, Gamba G (2004) Molecular physiology of cation-coupled Cl- cotransport: the SLC12 family. Pflugers Arch 447:580-593.
Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, et al. (2003) A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. NatGenet 35:349-356.
Helms C, Saccone NL, Cao L, Daw JA, Cao K, Hsu TM, et al. (2005) Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 118:466-476.
Hewett D, Samuelsson L, Polding J, Enlund F, Smart D, Cantone K, et al. (2002) Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 79:305-314.
Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, et al. (2000) Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164:6621-6632.
Huffmeier U, Lascorz J, Traupe H, Bohm B, Schurmeier-Horst F, Stander M, et al. (2005) Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris. J Invest Dermatol 125:906-912.
International PGC (2003) The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am J Hum Genet 73:430-437.
Jung LK, Roy AK, Chakkalath HR (1992) CD7 augments T cell proliferation via the interleukin-2 autocrine pathway. Cell Immunol 141:189-199.
Kopan R, Fuchs E (1989) The use of retinoic acid to probe the relation between hyperproliferation-associated keratins and cell proliferation in normal and malignant epidermal cells. J Cell Biol 109:295-307.
Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. JAmAcadDermatol 46:1-23.
Kulke R, Todt-Pingel I, Rademacher D, Rowert J, Schroder JM, Christophers E (1996) Co-localized overexpression of GRO-alpha and IL-8 mRNA is restricted to the suprapapillary layers of psoriatic lesions. J Invest Dermatol 106:526-530.
Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B (2001) Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med 194:855-861.
Langley RG, Krueger GG, Griffiths CE (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64 Suppl 2:ii18-23; discussion ii24-15.
Larregina AT, Falo LD, Jr. (2005) Changing paradigms in cutaneous immunology: adapting with dendritic cells. J Invest Dermatol 124:1-12.
Lazarovits AI, Osman N, Le Feuvre CE, Ley SC, Crumpton MJ (1994) CD7 is associated with CD3 and CD45 on human T cells. JImmunol 153:3956-3966.
Lebwohl M (2003) Psoriasis. Lancet 361:1197-1204.
Ledbetter JA, June CH, Grosmaire LS, Rabinovitch PS (1987) Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. ProcNatlAcadSciUSA 84:1384-1388.
Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199:125-130.
Lew W, Bowcock AM, Krueger JG (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'Type 1' inflammatory gene expression. Trends Immunol 25:295-305.
Liu Y, Krueger JG, Bowcock AM (2007) Psoriasis: genetic associations and immune system changes. Genes Immun 8:1-12.
Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, et al. (2005) Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 124:1275-1283.
Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866-873.
Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, et al. (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 102:19057-19062.
Lyman SD, Escobar S, Rousseau AM, Armstrong A, Fanslow WC (2000) Identification of CD7 as a cognate of the human K12 (SECTM1) protein. J Biol Chem 275:3431-3437.
Mansbridge JN, Knapp AM (1987) Changes in keratinocyte maturation during wound healing. J Invest Dermatol 89:253-263.
Martin ER, Bass MP, Kaplan NL (2001) Correcting for a potential bias in the pedigree disequilibrium test. Am J Hum Genet 68:1065-1067.
Matthews D, Fry L, Powles A, Weber J, McCarthy M, Fisher E, et al. (1996) Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet 14:231-233.
McKenzie BS, Kastelein RA, Cua DJ (2006) Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27:17-23.
Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W, et al. (1997) Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 6:1349-1356.
Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, et al. (2000) Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 66:1833-1844.
Nair RP, Stuart P, Ogura Y, Inohara N, Chia NV, Young L, et al. (2001) Lack of association between NOD2 3020InsC frameshift mutation and psoriasis. J Invest Dermatol 117:1671-1672.
Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, et al. (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78:827-851.
Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202:135-143.
Nickoloff BJ, Bonish B, Huang BB, Porcelli SA (2000) Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 24:212-225.
Nickoloff BJ, Xin H, Nestle FO, Qin JZ (2007) The cytokine and chemokine network in psoriasis. Clin Dermatol 25:568-573.
Pace KE, Lee C, Stewart PL, Baum LG (1999) Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. JImmunol 163:3801-3811.
Pan WH, Fann CS, Wu JY, Hung YT, Ho MS, Tai TH, et al. (2006) Han Chinese cell and genome bank in Taiwan: purpose, design and ethical considerations. HumHered 61:27-30.
Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174:1483-1489.
Perillo NL, Pace KE, Seilhamer JJ, Baum LG (1995) Apoptosis of T cells mediated by galectin-1. Nature 378:736-739.
Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG (1997) Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med 185:1851-1858.
Pisani M, Ruocco V (1984) 'Twin' psoriasis in monozygotic twins. Arch Dermatol 120:1418-1419.
Poirier F, Timmons PM, Chan CT, Guenet JL, Rigby PW (1992) Expression of the L14 lectin during mouse embryogenesis suggests multiple roles during pre- and post-implantation development. Development 115:143-155.
Quesada JR, Gutterman JU (1986) Psoriasis and alpha-interferon. Lancet 1:1466-1468.
Rabinovich GA, Iglesias MM, Modesti NM, Castagna LF, Wolfenstein-Todel C, Riera CM, et al. (1998) Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization. J Immunol 160:4831-4840.
Ragaz A, Ackerman AB (1979) Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1:199-214.
Ramirez-Bosca A, Martinez-Ojeda L, Valcuende-Cavero F, Castells-Rodellas A (1988) A study of local immunity in psoriasis. Br J Dermatol 119:587-595.
Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, et al. (1988) Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol 140:1401-1407.
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-426.
Sempowski GD, Lee DM, Kaufman RE, Haynes BF (1999) Structure and function of the CD7 molecule. Crit Rev Immunol 19:331-348.
Spandau U, Toksoy A, Goebeler M, Brocker EB, Gillitzer R (1998) MIG is a dominant lymphocyte-attractant chemokine in lichen planus lesions. J Invest Dermatol 111:1003-1009.
Speckman RA, Wright Daw JA, Helms C, Duan S, Cao L, Taillon-Miller P, et al. (2003) Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet 112:34-41.
Stillwell R, Bierer BE (2001) T cell signal transduction and the role of CD7 in costimulation. ImmunolRes 24:31-52.
Subrahmanyam G, Rudd CE, Schneider H (2003) Association of T cell antigen CD7 with type II phosphatidylinositol-4 kinase, a key component in pathways of inositol phosphate turnover. EurJImmunol 33:46-52.
Sun C, Mathur P, Dupuis J, Tizard R, Ticho B, Crowell T, et al. (2006) Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21. Hum Genet 119:113-125.
ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ (2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50:206-211.
Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD (1998) Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111:645-649.
Thewes M, Stadler R, Korge B, Mischke D (1991) Normal psoriatic epidermis expression of hyperproliferation-associated keratins. Arch Dermatol Res 283:465-471.
Tigalonowa M, Bjerke JR, Gallati H, Matre R (1989) Immunological changes following treatment of psoriasis with cyclosporin. Acta Derm Venereol Suppl (Stockh) 146:142-145; discussion 146.
Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M (1980) Psoriasis and HLA-Cw6. Br J Dermatol 102:179-184.
Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, et al. (1994) Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264:1141-1145.
van den Brule FA, Buicu C, Baldet M, Sobel ME, Cooper DN, Marschal P, et al. (1995) Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 209:760-767.
Veal CD, Capon F, Allen MH, Heath EK, Evans JC, Jones A, et al. (2002) Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 71:554-564.
Veal CD, Clough RL, Barber RC, Mason S, Tillman D, Ferry B, et al. (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 38:7-13.
Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, et al. (2004) Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 113:38-46.
Wang F, Lee E, Lowes MA, Haider AS, Fuentes-Duculan J, Abello MV, et al. (2006) Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 126:1590-1599.
Wells V, Mallucci L (1991) Identification of an autocrine negative growth factor: mouse beta-galactoside-binding protein is a cytostatic factor and cell growth regulator. Cell 64:91-97.
Weninger W, Carlsen HS, Goodarzi M, Moazed F, Crowley MA, Baekkevold ES, et al. (2003) Naive T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J Immunol 170:4638-4648.
Weninger W, von Andrian UH (2003) Chemokine regulation of naive T cell traffic in health and disease. Semin Immunol 15:257-270.
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R (2004) IL-22 increases the innate immunity of tissues. Immunity 21:241-254.
Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 93:6737-6742.
Yip SY (1984) The prevalence of psoriasis in the Mongoloid race. JAmAcadDermatol 10:965-968.
Young C, Allen MH, Cuthbert A, Ameen M, Veal C, Leman J, et al. (2003) A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasis. Exp Dermatol 12:506-509.
Zhang XJ, He PP, Wang ZX, Zhang J, Li YB, Wang HY, et al. (2002) Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. J Invest Dermatol 119:1361-1366.
Zheng J, Jin S, Shi R (2003) Confirmation of PSORS psoriasis susceptibility loci in a Chinese population. Arch Dermatol Res 295:14-18.
Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, et al. (2003) Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 13:69-78.
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38067-
dc.description.abstract乾癬是一種慢性、非傳染性的皮膚病,主要特徵是角質細胞過度增生並且分化不完全,以及皮膚內有許多活化的免疫細胞堆積。乾癬人口在白種人中約佔2-3%,而在亞洲蒙古人種中約只佔0.3%。我們找到一個五代遺傳的乾癬家族並且著手研究,患者間的乾癬病灶輕重程度不同,但呈現典型自體顯性遺傳。為了找出此家族的乾癬易感致病基因位置,我們利用382個 microsatellite markers 進行全基因體掃描定位。第17號染色體q25區域有很顯著與乾癬連鎖的證據,最高的雙點LOD值是在D17S928標記處,LOD值是7.164。我們接著在附近另外挑選六個標記進一步做多點聯鎖分析,也證實了在D17S928處與乾癬有連鎖 (LOD值是4.58)。接著在17q25區域我們以202個SNP markers進一步定位分析,證實在兩處有很強的連鎖,分別在D17S784附近 (以高解析度雙點與多點分析分別LOD值為 4.45與 7.67) 以及 17號染色體末端附近。因此我們的研究將乾癬基因定位到一段新的染色體位置,約3.8 Mb長的區域,與之前報導17q25上可能的乾癬基因位置不同而比較偏17號染色體末端。
為了找出此乾癬家族的致病突變,我們在這個區域針對了78個基因進行定序分析,並且找到四個在家族中會與疾病一起傳遞的基因變異,分別是CD7中的p.Ala201Val、 ZNF750中的c.-625A>C、 C17orf56中的p.Asp189Asn 以及 AATK中的 p.Ala568Thr。後兩者基因變異在其他乾癬家族中並不會隨著疾病一起傳遞,並且在正常人對照組中也有出現,因此沒有繼續對此兩個基因繼續研究。對CD7功能進行研究的結果並不支持CD7就是致病基因。但相反的,ZNF750基因的c.-625A>C突變會造成promoter功能下降42%,EMSA實驗結果顯示突變C allele上有核蛋白結合。此c.-625A>C突變也在另一位偶發型 (sporadic) 乾癬患者身上找到,但188位正常對照組中卻沒有人帶有,此突變總共出現佔中國人種乾癬患者的1.7% (信賴區間為0.2-5.84%)。本研究推測ZNF750基因突變可能會造成乾癬誘發。
zh_TW
dc.description.abstractPsoriasis is a chronic, noncontagious skin disorder characterized by overgrowth and incomplete differentiation of keratinocytes, as well as infiltration of the skin by activated immune cells. Psoriasis affects 2-3% of the Caucasian population, but only 0.3% in the Mongoloid population. We have investigated a five-generation extended family with variable severity of psoriatic lesions followed a classical autosomal dominant inheritance pattern. To identify the psoriasis susceptibility locus in this family, a genome-wide scan with 382 microsatellite markers was performed. The 17q25 region showed a highly significant linkage, with a maximum two-point LOD score of 7.164 at D17S928 (theta=0.01). Multipoint linkage analysis with six additional flanking markers confirmed the linkage at D17S928 (LOD score of 4.58). Further mapping with 202 SNP markers in the 17q25 region confirmed the tight linkage to markers both around D17S784 (LOD score 4.45 and 7.67 by high-resolution two-point and multipoint analysis, respectively) and around 17q terminus (LOD score 4.472 and 3.404). Our study thus maps a new locus for psoriasis, a 3.8 Mb region, which is distal to and distinct from the recent report of a putative susceptibility gene located in 17q25.
To identify the mutations responsible for the psoriasis in this family, we sequenced 78 genes within the region and found four genes variants, p.Ala201Val in CD7, c.-625A>C in ZNF750, p.Asp189Asn in C17orf56 and p.Ala568Thr in AATK co-segregated with the disease. The latter two variants were not studied further for absence of disease segregation in other familial psoriasis and presence of variants in normal subjects. Functional analyses of CD7 did not support CD7 as a disease-causing gene. In contrast, the c.-625A>C mutation in the ZNF750 resulted in a 42% reduction of the promoter activity, and the electrophoretic mobility shift assay demonstrated binding of nuclear protein(s) to the mutant C allele. The c.-625A>C mutation was found in another sporadic psoriasis patient but absent in 188 normal controls, together the mutation accounts for 1.7% (CI: 0.2-5.84%) of the Chinese psoriasis. This study suggests that ZNF750 mutations could contribute to psoriasis susceptibility.
en
dc.description.provenanceMade available in DSpace on 2021-06-13T15:59:47Z (GMT). No. of bitstreams: 1
ntu-97-D91445004-1.pdf: 4710472 bytes, checksum: 754c9fbdbbbbc6dc9a0829f83bf11f41 (MD5)
Previous issue date: 2008
en
dc.description.tableofcontentsCONTENTS
中 文 摘 要……………………………………………………………………… I
ABSTRACT………………………………………………………………………. III
ABBREVIATIONS………………………………………………………………. V
CONTENTS………………………………………………………………………. VI
Chapter 1: INTRODUCTION…………………………………………………… 1
1.1. Clinical and histological features of Psoriasis………………………………. 1
1.2. Evidence for cellular immunity in Psoriasis………………………………… 3
1.3. Differentiation of keratinocytes in psoriastic plaques………………………. 4
1.4 Cellular interaction and cytokine networks of psoriatic lesions…………….. 6
1.5. Development of psoriatic plaques…………………………………………… 10
1.5.1. Initiation……………………………………………………………… 10
1.5.2. Acute lesion………………………………………………………….. 11
1.5.3. Chronic lesion……………………………………………………….. 11
1.6. Therapeutics in Psoriasis…………………………………………………….. 12
1.7. Genetic studies of Psoriasis………………………………………………….. 15
17.1 PSORS1……………………………………………………………… 16
1.7.2 PSORS2……………………………………………………………... 17
1.7.3 PSORS3-9………………………………………………………….... 19
Chapter 2: SPECIFIC AIMS…………………………………………………….. 23
Chapter 3: MATERIALS AND METHODS…………………………………..... 25
3.1. Patients………………………………………………………………………. 25
3.2. Genotyping………………………………………………………………….. 26
3.3. Single nucleotide polymorphism selection and typing……………………… 27
3.4. Statistical analyses of typing data………………………………………….... 28
3.5 HLA genotyping……………………………………………………………... 29
3.6. DNA sequence analysis……………………………………………………… 30
3.7. Functional analysis of the CD7 gene………………………………………… 31
3.7.1. Flow cytometric analysis of CD7……………………………………. 31
3.7.2. T-cell activation…………………………………………………….... 32
3.7.3. Generation of CD7 stable transfectants……………………………… 33
3.7.4. Cell activation of CD7 stable transfectants………………………….. 34
3.7.5. Galectin-1 cell death assay…………………………………………... 34
3.8 Functioal promoter analysis of ZNF750 gene……………………………….. 35
3.8.1 Transcription factor binding site identification………………………. 35
3.8.2. Real time quantitative PCR………………………………………….. 35
3.8.3 Reporter constructs…………………………………………………... 36
3.8.4. Transient transfection and luciferase assay………………………….. 37
3.8.5 Electrophoretic mobility shift assay…………………………………. 38
Chapter 4: RESULTS…………………………………………………………….. 41
4.1. Clinical and histological features in the index family……………………….. 41
4.2. Mapping of psoriasis to chromosome 17q terminus…………………………. 42
4.3. Confirmation of linkage with SNP markers…………………………………. 43
4.4 HLA-B and C alleles are not linked with the disease severity ……………… 44
4.5 Sequence of candidate genes on chromosome 17q terminus………………… 45
4.6 Novel gene variants cosegregated with the disease…………………………. 47
4.7 Selection of gene variants for functional analysis…………………………… 48
4.8 Analysis of the CD7 p.Ala201Val variant…………………………………… 49
4.8.1 CD7 expression on T and NK cells………………………………….. 49
4.8.2. Costimulatory activity of CD7 in PBMC cells of patients…………... 50
4.8.3. CD7 expresstion and costimulatory activity of stable transfectants…. 50
4.8.4. Galectin-1-mediated death through CD7…………………………….. 51
4.9 Fuctional analysis of ZNF750 supports ZNF750 as a disease-causing gene…52
4.9.1. Alignment of the 5’ genomic DNA sequence of ZNF750……………52
4.9.2. Prediction of transcription factor binding sites and TATA box on
ZNF750 promoter……………………………………………………. 52
4.9.3. The expression of ZNF750 transcripts………………………………. 53
4.9.4. ZNF750 c.-625A>C mutation decreases ZNF750 promoter activity… 53
4.9.5. Gain of Transcription factor binding to the mutant C allele…………. 54
4.9.6. ZNF750 sequence variations in other patients with psoriasis……….. 54
Chapter 5: DISCUSSION…………………………………………………...…… 57
5.1. The discrepancy in the psoriasis susceptibility locus on 17q25……………... 57
5.2. Linkage analysis……………………………………………………………... 58
5.3. The heterozygosity of SNP markers…………………………………………. 59
5.4. The SNPs identified in the index family…………………………………….. 59
5.5. The variation p.Ala201Val of CD7 does not affect its functionality………… 60
5.6. Compared with previous report in ZNF750…………………………………. 63
5.7. The expression of ZNF750 transcripts………………………………………. 64
5.8. The role of Ets family in the pathogenesis mediated by the c.-625A>C
mutation……………………………………………………………………… 64
5.9. ZNF750 sequence variations in other patients with psoriasis……………….. 65

TABLES…………………………………………………………………………… 67
FIGURES …………………………………………………………………………. 76
REFERENCES……………………………………………………………………. 113
APPENDIX……………………………………………………………………….. 126
dc.language.isoen
dc.subject全基因體掃瞄zh_TW
dc.subject乾癬zh_TW
dc.subject連鎖zh_TW
dc.subjectCD7zh_TW
dc.subjectZNF750zh_TW
dc.subjectpsoriasisen
dc.subjectgenome-wide scanen
dc.subjectZNF750en
dc.subjectCD7en
dc.subjectlinkageen
dc.title乾癬致病基因之鑑定與分析zh_TW
dc.titleIdentification and characterization of a Psoriasis susceptibility geneen
dc.typeThesis
dc.date.schoolyear96-2
dc.description.degree博士
dc.contributor.oralexamcommittee鄔哲源(Jer-Yuarn Wu),廖楓(Fang Liao),蕭白忍(Pauline H. Yen),范盛娟(Cathy S. J. Fann)
dc.subject.keyword乾癬,全基因體掃瞄,連鎖,CD7,ZNF750,zh_TW
dc.subject.keywordpsoriasis,genome-wide scan,linkage,CD7,ZNF750,en
dc.relation.page128
dc.rights.note有償授權
dc.date.accepted2008-04-29
dc.contributor.author-college醫學院zh_TW
dc.contributor.author-dept微生物學研究所zh_TW
顯示於系所單位:微生物學科所

文件中的檔案:
檔案 大小格式 
ntu-97-1.pdf
  未授權公開取用
4.6 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved